A recent review highlights inflammation’s dual role in cancer progression and how emerging tools like AI and imaging biomarkers are enhancing personalized immunotherapy.
Key Details
- 1Chronic inflammation promotes tumorigenesis, survival, and therapy resistance, but can also suppress cancer depending on context.
- 2Key pathways: NF-κB, STAT3, IL-6, COX-2, and specific immune cells modulate the tumor microenvironment.
- 3Immunotherapies show varying efficacy (20–40% response rates); biomarkers like CRP, IL-6, and imaging data are key for patient stratification.
- 4Combination strategies (immunotherapy plus anti-inflammatories or microbiome modulators) are under clinical investigation.
- 5AI models incorporating imaging and multi-omic data are enabling real-time treatment personalization; Stanford’s 2024 model integrates imaging/text.
- 6Emerging tools include liquid biopsies, single-cell omics, gene editing, and nanotechnology for more precise disease monitoring.
Why It Matters
Understanding how inflammation drives cancer and therapy resistance is crucial for radiology, especially as integration of imaging, AI, and novel biomarkers underpins the move toward precision oncology. These advances offer new avenues for diagnosis, patient stratification, and monitoring treatment response using imaging and AI-driven tools.
Source
EurekAlert
Related News
•EurekAlert
AI Accelerates Radiopharmaceuticals, Boosts Personalized Dosimetry in Cancer
Machine learning is driving advancements in radiopharmaceutical drug discovery and optimizing patient-specific dosimetry for precision cancer therapy.
•EurekAlert
Physicians Overly Trust Erroneous AI, Ignore Contradictory Evidence
Physicians tend to trust incorrect AI advice, even when evidence contradicts it, suggesting risks in clinical decision-making with AI tools.
•EurekAlert
Concerns Raised Over Unverified Datasets in AI Health Prediction Models
A new study finds widely used AI health prediction models are built on datasets with unverifiable origins, raising safety and validity concerns.